17 Nov 04
School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.
09 Nov 04
Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
05 Nov 04
Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
04 Nov 04
Prostate cancer is the most common male malignancy in Western countries. Surgery and radiological procedures for localized prostate cancer offer the possibility for curative treatment. Prostate cancer also represents one of the most lucrative oncology indications for the pharmaceutical industry because drug-based treatment is often very effective at delaying disease progression, even in advanced disease, which encourages high-volume and long-term usage. The use of hormonal manipulation for advan
01 Nov 04
The pharmaceutical and biotech industries are important contributors to the economies of European countries and are also major employers. If companies in these sectors are to continue to base themselves in Europe they must be seen as positive forces in the field of technology and healthcare rather than a negative drain on a country's finances.
Dr Faiz Kermani
29 Oct 04
The environment for drug development is tougher than it has ever been, with companies having to deal with a variety of political, regulatory, social and economic pressures in order to get their products to market. Few biotech companies have been able to devise a strategy to succeed in this hostile environment on their own, but there is no shortage of new entrants in the market.
Dr Faiz Kermani
29 Oct 04
Hepatocellular carcinoma is the fifth commonest cancer worldwide with about one million new cases diagnosed annually. It is estimated that the incidence of hepatocellular carcinoma in the seven major pharma markets will continue to rise over the next decade. There is no gold standard therapy - the market is characterized by high levels of unmet need, large patient potential and high commercial potential. To mark the publication of its new feature "Hepatocellular Carcinoma" LeadDiscovery's analys
28 Oct 04
Learn about new methods and innovative tools to help you with your translational research.
22 Oct 04
Vaccines represent one of the most effective weapons in the armoury of modern medicine. In an age where the benefits of healthcare interventions in relation to their costs are frequently debated in the media, it is easy to forget the tremendous health contribution that vaccines have made and the millions of lives they have saved.
Dr Faiz Kermani
22 Oct 04
Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $300 million/drug in costs. Petra Biotek are set to knock down these barriers through their computer-based Cycle Dose Modification system. The positive impact that this technology is expected to have on the clinical developm
22 Oct 04
Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.
18 Oct 04
The OTC market has become highly competitive for pharmaceutical manufacturers, particularly in the US, which is the largest consumer society in the world. There have been a number of consolidations and acquisitions in the pharmaceutical sector to help companies boost their presence in the OTC field.
Dr Faiz Kermani
15 Oct 04
Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by colorectal cancer. Better use of the pharmacological and interventional treatments available would dramatically improve the lives of the millions of PAD patients while at the same time ballooning the r
15 Oct 04
Recruitment is a very inexact science – the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
14 Oct 04
The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...
11 Oct 04
Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...
07 Oct 04
The demographics of HIV patients are shifting, with the average age of those infected with HIV ever increasing due to longer life expectancy and higher survival rates. However, with increasingly complex infections and drug resistance developing in long term patients, novel medications and new combinations are now being launched to continue the fight...
05 Oct 04
Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Bayer's BAY 43-9006 is a
01 Oct 04
As the dust settles on Merck's withdrawal of Vioxx's, LeadDiscovery investigates the impact that this will have on the treatment of pain, R&D activity directed towards the identification of new approaches, and on pharmaceutical sales relating to COX-2 inhibitors and related drug classes
30 Sep 04
The market for Alzheimer's therapy is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets. Alzheimer's disease market in the seven major markets is worth $4.7 billion and will increase to $6.1 billion by the year 2005 and $ 7.8 billion by the year 2010. The major unmet need in this market is for disease modification and disease prevention. Recent findings by British researchers showing that targeting the neuronal adaptor protein X11beta can r
29 Sep 04
The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will lead to an expansion of the already $30 billion neurodegenerative market. Despite the growth of generic products, Parkinson's disease drug revenues grew an impressive 17% across the seven major markets
28 Sep 04
Until a few years ago very few people would have given credence to the idea that an ongoing war is being waged in the battleground of the digestive system between good and bad bacteria, but with a marketing onslaught akin to the Star Wars world it parallels the makers of probiotics have now introduced the concept to Britain.
22 Sep 04
Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows olmesartan to have additional anti- inflammatory activity in hypertensive patients with vascular inflammation. This may confer additional therapeutic benefit since inflammation is an etiological compo
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.